Work from Dr. Fiona Powrie’s group at University of Oxford has identified an interaction between the receptor for the immune molecule interleukin-22 (IL-22) and alterations of the KRAS gene, showing that they cooperate in promoting excessive proliferation of colon cancer cells. As KRAS mutations are present in almost half of all colorectal tumors and are poorly responsive to standard therapies, these results suggest that patients with a mutant KRAS and high IL-22 receptor levels may benefit from alternative strategies involving IL-22 modulation. This study is published in Clinical Cancer Research and is described in more detail in a University of Oxford press release.
IL-22 Pathway Identified as a New Target in Colon Cancers with Mutant KRAS
Aug 20, 2020